Research Frontiers, Inc. (REFR) Trades at $1.05 After Triangle; China Biologic Products Holdings, Inc. (CBPO) Had 2 Analysts Last Week

November 15, 2017 - By Louis Casey

Research Frontiers, Inc. (REFR) formed triangle with $1.11 target or 6.00% above today’s $1.05 share price. Research Frontiers, Inc. (REFR) has $25.25 million valuation. The stock decreased 5.41% or $0.06

on November 14, reaching $1.05. About shares traded. Research Frontiers, Inc. (NASDAQ:REFR) has declined 72.08% since November 15, 2016 and is downtrending. It has underperformed by 88.78% the S&P500.

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products had 6 analyst reports since September 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Friday, October 13. Jefferies maintained China Biologic Products Holdings, Inc. (NASDAQ:CBPO) on Thursday, August 3 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Friday, September 4. Jefferies maintained it with “Buy” rating and $128.0 target in Tuesday, September 12 report. The company was maintained on Monday, June 12 by Jefferies. See China Biologic Products Holdings, Inc. (NASDAQ:CBPO) latest ratings:

13/10/2017 Broker: Jefferies Rating: Buy New Target: $128.0 Maintain
12/09/2017 Broker: Jefferies Rating: Buy New Target: $128.0 Maintain
03/08/2017 Broker: Jefferies Rating: Buy New Target: $128.0000 Maintain
12/06/2017 Broker: Jefferies Rating: Buy New Target: $140.0000 Maintain

The stock decreased 1.25% or $1.1 on November 14, reaching $86.58. About shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 1.48% since November 15, 2016 and is downtrending. It has underperformed by 18.18% the S&P500.

Investors sentiment decreased to 0.65 in 2017 Q2. Its down 0.37, from 1.02 in 2017Q1. It fall, as 27 investors sold China Biologic Products Holdings, Inc. shares while 42 reduced holdings. 11 funds opened positions while 34 raised stakes. 15.29 million shares or 21.23% less from 19.41 million shares in 2017Q1 were reported. State Common Retirement Fund accumulated 12,456 shares or 0% of the stock. Public Employees Retirement Sys Of Ohio has 14,791 shares for 0.01% of their portfolio. Citigroup reported 11,748 shares. Goldman Sachs Gru reported 61,404 shares. Fil has 861,623 shares. Standard Life Invests Ltd has 0.05% invested in China Biologic Products Holdings, Inc. (NASDAQ:CBPO) for 131,045 shares. Ubs Asset Management Americas stated it has 0% of its portfolio in China Biologic Products Holdings, Inc. (NASDAQ:CBPO). Martin Currie stated it has 1,700 shares. National Bank Of Mellon Corporation invested in 0.02% or 586,459 shares. Ahl Partners Llp reported 0.02% in China Biologic Products Holdings, Inc. (NASDAQ:CBPO). Wells Fargo And Mn owns 113 shares. 1.42M are held by Blackrock. Northern invested in 0% or 3,300 shares. York Global Limited Liability Com reported 0.19% stake. First Mercantile Tru invested 0.02% of its portfolio in China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

Investors sentiment increased to 1.14 in 2017 Q2. Its up 0.64, from 0.5 in 2017Q1. It improved, as 1 investors sold Research Frontiers, Inc. shares while 6 reduced holdings. 4 funds opened positions while 4 raised stakes. 4.20 million shares or 10.52% less from 4.70 million shares in 2017Q1 were reported. Moreover, Vanguard Inc has 0% invested in Research Frontiers, Inc. (NASDAQ:REFR) for 557,929 shares. 27,500 are owned by Raymond James And Assoc. Georgia-based Homrich & Berg has invested 0% in Research Frontiers, Inc. (NASDAQ:REFR). Blackrock holds 0% of its portfolio in Research Frontiers, Inc. (NASDAQ:REFR) for 710,455 shares. Northern, a Illinois-based fund reported 43,389 shares. First Allied Advisory Svcs Incorporated reported 0% stake. Outfitter Advisors owns 0.02% invested in Research Frontiers, Inc. (NASDAQ:REFR) for 36,000 shares. Geode Cap Ltd Llc owns 95,951 shares. California Employees Retirement System invested 0% in Research Frontiers, Inc. (NASDAQ:REFR). Cambridge Investment Research Advsrs owns 17,700 shares. 19,501 are held by Wells Fargo And Mn. Tower Rech Lc (Trc) reported 2,546 shares. Commercial Bank Of America Corporation De holds 0% or 2,650 shares. Morgan Stanley has 10,898 shares. Susquehanna Group Llp holds 11,564 shares.

Analysts await Research Frontiers, Inc. (NASDAQ:REFR) to report earnings on March, 12. They expect $-0.03 earnings per share, up 50.00% or $0.03 from last year’s $-0.06 per share. After $-0.01 actual earnings per share reported by Research Frontiers, Inc. for the previous quarter, Wall Street now forecasts 200.00% negative EPS growth.

Among 3 analysts covering Research Frontiers (NASDAQ:REFR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Research Frontiers had 4 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Outperform” rating by WestPark Capital on Wednesday, September 28. The firm has “Hold” rating by Zacks given on Wednesday, August 12. The firm earned “Hold” rating on Friday, August 5 by Craig Hallum.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>